- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Sequester Forcing Chemo Treatments into Hospital Settings, Costing Taxpayers More in the End
The federal sequester trims Medicare payments for cancer patients receiving chemotherapy in doctors' offices in an effort to save the government money. Instead, it will end up costing more in the long run, according to the president of the American Society of Clinical Oncology (ASCO).
PLAINSBORO, N.J. — For all the complaints about the federal sequester, at least it’s saving the American taxpayer money, right? Not so when certain Medicare patients need chemotherapy. What’s worse, those patients are sent to less convenient settings – typically hospitals away from their local cancer treatment center – for care that ends up costing Medicare more in the end, several experts told Evidence-Based Oncology in the just-published August issue.
“It’s quite an amazing paradox,” Dr. Cliff Hudis, president of the American Society of Clinical Oncology, told EBO, an indexed news publication that is a supplement to The American Journal of Managed Care.
No one knows for certain how much the problem is costing taxpayers, but the amount is growing the longer the sequester lasts without a solution to this particular quandary.
Hudis and others tell EBO the sequester’s 2 percent cut to Medicare reimbursements has extended to local physicians and cancer centers, who cannot absorb that loss on expensive chemotherapy drugs. So these local providers are forced to refer patients to less convenient hospital settings, where it costs Medicare more money to provide chemotherapy.
Add the cost of this phenomenon up, patient by patient, and the tally is expected to be large. EBO reports an estimate by Milliman, the actuarial consultant, that chemotherapy in a hospital costs $6,500 more per year than in a community setting.
U.S. Rep. Renee Ellmers, R-N.C., has received bipartisan support for legislation that would exempt chemotherapy from the 2 percent cut. “What’s needed is momentum and public awareness,” she told EBO.
For the full article, click here.
CONTACT: Nicole Beagin (609) 716-7777 x 131
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
